Abstract: Cell expansion systems and methods of use are provided. The cell expansion systems generally include a hollow fiber cell growth chamber, and first and second circulation loops (intracapillary loops and extracapillary loops) associated with the interior of the hollow fibers and exterior of the hollow fibers, respectively. Detachable flow circuits and methods of expanding cells are also provided.

Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.

Abstract: The invention provides a new method for DNA sequencing called “natural sequencing by synthesis” (nSBS). According to the method, DNA that includes a desired sequence is synthesized using a dNTP mix with a small percentage of fluorescently-labeled nucleotides. The fluorescent label is cleavable. In contrast to previous methods that utilize 100% labeled nucleic acids, use of a small percentage of labeled nucleic acids minimizes the distortion of the natural structure of the extending DNA strand and the DNA polymerase. Using the disclosed methods with less than 10,000 copies of template DNA and 10% of the nucleotides labeled, long homopolymer stretches up to 20 bases can be sequenced with high accuracy and Q20 (with 99% accuracy) read lengths of up to 1,000 bases can be achieved. A Q20 read length of greater than 100 bases can potentially be achieved, even if the sequencing is performed with 1,000 copies of a template and 10% of the nucleotides labeled.

Abstract: An efficient and accurate method of identifying a target biomolecule in a sample by using target molecule-probe binding frequencies is disclosed.

Abstract: A method of alleviating pain associated with tissue damage includes applying salmon thrombin at a tissue damage site, as a single substance in liquid form, or as a powder, a foam, and/or a gel that includes salmon thrombin. A pain relief substance includes a salmon thrombin preparation.

Abstract: The invention relates to a promoter selected from a group of nucleic acids consisting of (a) a nucleic acid having the nucleotide sequence of SEQ ID NO:1; (b) a nucleic acid having a nucleotide sequence derived from SEQ ID NO:1, wherein not more than 10 nucleotides have been added, deleted, substituted and/or inverted from the nucleic acid of SEQ ID NO:1; and (c) a nucleic acid sequence having at least 70% identity with the nucleic acid of (a); wherein the promoter has a length of up to and including 27 nucleotides and wherein the promoter according to options (b) and (c) exhibits at least the 70% of the promoter activity of SEQ ID NO:1 as measured by the amount of recombinant protein produced.

Abstract: The present invention provides a reporter gene containing cell line with increased specificity and/or sensitivity for a particular extracellular signal of interest so that it can be used in a gene-reporter assay to accurately determine the presence and/or level of the extracellular signal of interest in the presence of other extracellular signals that are capable of activating the same signal transduction pathway as the extracellular signal of interest or that are capable of activating another signal transduction pathway capable of modulating the transcription of the reporter gene.

Abstract: Described herein are primers and probes useful for the binding, detecting, differentiating, isolating, and sequencing of influenza A, influenza B, 2009 influenza A/H1N1, and a 2009 influenza A/H1N1 RNA sequence mutation associated with oseltamivir resistance.

Abstract: A method of double crossover homologous recombination in a host cell comprising: a first homologous recombination event between a donor DNA molecule comprising a first element of a selectable allele and an acceptor DNA molecule comprising a second element of the selectable allele in the host cell, thereby to form a product of the first homologous recombination event in the host cell; and a second homologous recombination event within the product of the first homologous recombination event, thereby to form a product of the second homologous recombination event in the host cell which confers a selectable phenotype on the host cell, wherein the selectable phenotype arises following and in dependency on the formation of a selectable allele from the first and second elements of the selectable allele.

Abstract: A childbirth control system is provided to control the labor process of a patient. The patient's physical information of the patient and her fetus is continuously obtained during the labor via a plurality of diagnosis devices connected to a user terminal. The system includes an analysis module, which generates a childbirth progress data by continuously comparing the series of patient's measurement data with a series of reference measurement data. The childbirth progress data is provided on the user terminal to show the current progress of the childbirth as well as suggestions as to alternative childbirth method and medical treatment options. The system also provides the childbirth progress data to the user terminal of remotely located medical service providers, and allows them to remotely assist the childbirth process.

Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.

Abstract: Methods and materials are provided for integrating heterologous nucleic acids into the genome of a cell or virus without disrupting expression of genes adjacent to the insertion site.

Abstract: Ultraviolet radiation (UVR) has profound effects on human skin. However, its effects on the global transcriptome in vivo have not been well characterized. In addition, the contribution of the UVA component of UVR has not been previously assessed in vivo. Disclosed herein is the identification of sets of genes that are either up-regulated or down-regulated in response to UVA exposure. The gene sets described herein can be used to accurately identify skin samples that have been exposed to UVA and to assess the ability of a sun protection product to block the effects of UVA.

Abstract: Devices, methods, and systems are described for administration to at least one biological tissue of at least one device including at least one altered microorganism. In an embodiment, the altered microorganism includes at least one nucleic acid construct encoding at least one therapeutic agent.

Abstract: Provided herein are methods and devices for single object detection. The methods and devices can be used to identify a plurality epigenetic markers on a genetic material, or a chromatin, encompassing fragments thereof. The invention provides for the characterization of the genetic material flowing through a channel in a continuous body of fluid based on detection of one or more properties of the genetic material. The methods and systems provided herein allow genome-wide, high-throughput epigenetic analysis and overcome a variety of limitations common to bulk analysis techniques.

Abstract: In the method for introducing a noncanonical amino acid residue into a desired position in a protein, the structure of tRNA is so modified as to have improved affinity for aminoacyl-tRNA synthetase or improved specificity to aminoacyl-tRNA synthetase. An unnatural base is contained at any position in tRNA, whereby the efficiency of aminoacylation of the tRNA with a noncanonical amino acid can be improved.

Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.

Abstract: Provided are a method for analyzing metastasis of head and neck cancer to a cervical lymph node, and a tumor marker for head and neck cancer used therein. Specifically, provided is a method for analyzing metastasis of head and neck cancer to a cervical lymph node, involving: measuring an expression level of at least one gene selected from the group consisting of genes represented by SEQ ID NOS: 1 to 36 in the sequence listing in a cervical lymph node sample; and comparing the aforementioned expression level with a reference value. Also provided is a tumor marker for head and neck cancer used in the aforementioned method for analyzing cervical lymph node metastasis, including at least one gene selected from the group consisting of genes represented by SEQ ID NOS: 1 to 36 in the sequence listing, and/or an expression product of the aforementioned gene and/or an expression level thereof.

Abstract: A method of detecting the presence of specific human papilloma virus and host cell biomarkers associated with head and neck tumors in biological samples, like saliva, blood or biopsy tissue, obtained from a subject.

Abstract: The present invention provides a method of screening a subject for mutations in the TRAPPC9 gene that are associated with developmental disabilities. The present invention also provides proteins that are associated with developmental disabilities including a truncation of NIBP. Also provided are nucleotide sequences encoding such proteins and methods of screening subjects to identify nucleotide sequences or proteins associated with developmental disabilities.